Literature DB >> 12438324

Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice.

Franck Biet1, Laurent Kremer, Isabelle Wolowczuk, Myriam Delacre, Camille Locht.   

Abstract

Interleukin-18 (IL-18) and IL-12 play a critical role in the expression of cell-mediated immunity involved in host defense against intracellular pathogens. Both cytokines are produced by macrophages and act in synergy to induce gamma interferon (IFN-gamma) production by T, B, and natural killer cells. In the present study, we analyzed both cellular and humoral responses upon infection with IL-18-secreting BCG of BALB/c and C3H/HeJ mice, two strains known to differ in their ability to support the growth of BCG. The cDNA encoding mature IL-18 was fused in frame with the alpha-antigen signal peptide-coding sequence, cloned downstream of the mycobacterial hsp60 promoter and expressed in BCG. IL-18 produced by the recombinant BCG strain was functional, as judged by NF-kappaB-mediated luciferase induction in a tissue culture assay. When susceptible mice were infected with IL-18-producing BCG, their splenocytes were found to produce higher amounts of Th1 cytokines after stimulation with mycobacterial antigens than the splenocytes of mice infected with the nonrecombinant BCG. This was most prominent for IFN-gamma, although the mycobacterial antigen-specific secretion of granulocyte-macrophage colony-stimulating factor and IL-10 was also augmented after infection with the recombinant BCG compared to infection with nonrecombinant BCG. In contrast, the immunoglobulin G levels in serum against mycobacterial antigens were lower when the mice were infected with IL-18-producing BCG compared to infection with nonrecombinant BCG. The IL-18 effect was delayed in BALB/c compared to C3H/HeJ mice. These results indicate that the production of IL-18 by recombinant BCG may enhance the immunomodulatory properties of BCG further toward a Th1 profile. This may be particularly useful for immunotherapeutic or prophylactic interventions in which a Th1 response is most desirable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438324      PMCID: PMC132979          DOI: 10.1128/IAI.70.12.6549-6557.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

Review 1.  Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens.

Authors:  Franck Biet; Camille Locht; Laurent Kremer
Journal:  J Mol Med (Berl)       Date:  2001-12-08       Impact factor: 4.599

2.  Purification and characterization of the human interleukin-18 receptor.

Authors:  K Torigoe; S Ushio; T Okura; S Kobayashi; M Taniai; T Kunikata; T Murakami; O Sanou; H Kojima; M Fujii; T Ohta; M Ikeda; H Ikegami; M Kurimoto
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

Review 3.  The role of Th2 type CD4+ T cells and Th2 type CD8+ T cells in asthma.

Authors:  K J Erb; G Le Gros
Journal:  Immunol Cell Biol       Date:  1996-04       Impact factor: 5.126

4.  Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.

Authors:  H W Herr; V P Laudone; R A Badalament; H F Oettgen; P C Sogani; B D Freedman; M R Melamed; W F Whitmore
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

5.  Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation.

Authors:  P J Sansonetti; A Phalipon; J Arondel; K Thirumalai; S Banerjee; S Akira; K Takeda; A Zychlinsky
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

6.  In vivo immunomodulation following intradermal injection with DNA encoding IL-18.

Authors:  L Kremer; L Dupré; I Wolowczuk; C Locht
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

7.  Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigen.

Authors:  K Matsuo; R Yamaguchi; A Yamazaki; H Tasaka; T Yamada
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

8.  A new series of mycobacterial expression vectors for the development of live recombinant vaccines.

Authors:  A Baulard; L Kremer; P Supply; D Vidaud; J M Bidart; D Bellet; C Locht
Journal:  Gene       Date:  1996-10-17       Impact factor: 3.688

9.  Defective NK cell activity and Th1 response in IL-18-deficient mice.

Authors:  K Takeda; H Tsutsui; T Yoshimoto; O Adachi; N Yoshida; T Kishimoto; H Okamura; K Nakanishi; S Akira
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

Review 10.  T cell response to Mycobacterium tuberculosis.

Authors:  I M Orme; P Andersen; W H Boom
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

View more
  16 in total

1.  A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.

Authors:  Jose C Ferraz; Evangelos Stavropoulos; Min Yang; Steve Coade; Clara Espitia; Douglas B Lowrie; M Joseph Colston; Ricardo E Tascon
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

Review 2.  [Immunology of tuberculosis: impact on the development of novel vaccines].

Authors:  T Ulrichs; S H E Kaufmann
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

3.  Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model.

Authors:  Rajpal S Kashyap; Aliabbas A Husain; Shweta H Morey; Milind S Panchbhai; Poonam S Deshpande; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  J Immune Based Ther Vaccines       Date:  2010-05-28

4.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 5.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 6.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

Review 7.  Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Authors:  Yi Luo; Jonathan Henning; Michael A O'Donnell
Journal:  Clin Dev Immunol       Date:  2011-09-15

8.  Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor.

Authors:  Sabine Ehrt; Xinzheng V Guo; Christopher M Hickey; Marvin Ryou; Mercedes Monteleone; Lee W Riley; Dirk Schnappinger
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

9.  IL-18 does not increase allergic airway disease in mice when produced by BCG.

Authors:  L Amniai; F Biet; P Marquillies; C Locht; J Pestel; A-B Tonnel; C Duez
Journal:  J Biomed Biotechnol       Date:  2007

10.  Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated Adults.

Authors:  Piotr Szpakowski; Franck Biet; Camille Locht; Małgorzata Paszkiewicz; Wiesława Rudnicka; Magdalena Druszczyńska; Fabrice Allain; Marek Fol; Joël Pestel; Magdalena Kowalewicz-Kulbat
Journal:  J Immunol Res       Date:  2015-08-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.